Hepion shelves Phase II NASH trial amid shallow cash resources
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.
![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/shutterstock_1121928752.jpg)
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.
The observational study will assess the clinical and workflow benefits of using Hyperfine’s Swoop system in detecting amyloid abnormalities in Alzheimer’s patients.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
Cleerly touts new data for AI cardiovascular software
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints
Gedeon Richter adopts TransPerfect’s trial management solutions